CXCL10 and neoplasm: At lower effector to target ratios, where no statistically significant tumor growth inhibition was noted from the addition of CD16+ NK92 cells alone, C-7 resulted in a strong enhancement of antitumor activity, suggesting that the combination of transfer of allogeneic NK cells and NK cell engaging bispecific antibodies could be of interest and could facilitate recruitment of NK cells to the tumor microenvironment directly, as well as via the production of CXCL10.